Literature DB >> 9539647

Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C.

M Y Sheikh1, R A Wright, J B Burruss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9539647     DOI： 10.1023/a:1018854906444

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  23 in total

1.  [Porphyria cutanea tarda and chronic hepatitis C. Course after interferon therapy].

Authors:  D Grasset; J Nougué; C Seigneuric; M Landreaud; J J Voigt
Journal:  Gastroenterol Clin Biol       Date:  1994

2.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

3.  Porphyria cutanea tarda and antibodies to hepatitis C virus.

Authors:  J P Lacour; I Bodokh; J Castanet; S Bekri; J P Ortonne
Journal:  Br J Dermatol       Date:  1993-02       Impact factor: 9.302

4.  Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment.

Authors:  O Reichard; H Glaumann; A Frydén; G Norkrans; R Schvarcz; A Sönnerborg; Z B Yun; O Weiland
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

5.  Is hepatitis C virus infection a trigger of porphyria cutanea tarda?

Authors:  C Herrero; A Vicente; M Bruguera; M G Ercilla; J M Barrera; J Vidal; J Terés; J M Mascaró; J Rodés
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

6.  Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association.

Authors:  S Fargion; A Piperno; M D Cappellini; M Sampietro; A L Fracanzani; R Romano; R Caldarelli; R Marcelli; L Vecchi; G Fiorelli
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

7.  Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C.

Authors:  M Shindo; A M Di Bisceglie; L Cheung; J W Shih; K Cristiano; S M Feinstone; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

8.  Mechanism of iron potentiation of hepatic uroporphyria: studies in cultured chick embryo liver cells.

Authors:  H L Bonkovsky
Journal:  Hepatology       Date:  1989-09       Impact factor: 17.425

9.  Response to interferon alpha therapy is influenced by the iron content of the liver.

Authors:  D H Van Thiel; L Friedlander; S Fagiuoli; H I Wright; W Irish; J S Gavaler
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

10.  Genotypic analysis of hepatitis C virus in American patients.

Authors:  K Mahaney; V Tedeschi; G Maertens; A M Di Bisceglie; J Vergalla; J H Hoofnagle; R Sallie
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425
View more
  3 in total

Review 1.  Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP.

Authors:  Alexandru Mester; Ondine Lucaciu; Lidia Ciobanu; Dragos Apostu; Aranka Ilea; Radu Septimiu Campian
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

2.  Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C.

Authors:  J D Rich; E Mylonakis; R Nossa; R M Chapnick
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

3.  Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.

Authors:  James Azim; Heather McCurdy; Richard-H Moseley
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.